Select a medication above to begin.
Keytruda
pembrolizumab
Adult Dosing .
Dosage forms: INJ
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments
melanoma
- [unresectable or metastatic dz]
- Dose: 200 mg IV q3wk; Alt: 400 mg IV q6wk
- [stage IIB, IIC, or III dz, adjuvant tx]
- Dose: 200 mg IV q3wk for up to 12mo; Alt: 400 mg IV q6wk for up to 12mo
non-small cell lung CA
- [nonsquamous metastatic dz, first-line tx, combo tx]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo; Info: for pts w/ no EGFR or ALK genomic tumor aberrations
- [squamous metastatic dz, first-line tx, combo tx]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo
- [stage III unresectable or metastatic dz, first-line tx, monotherapy]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo; Info: for pts w/ PD-L1-expressing tumor w/ no EGFR or ALK genomic tumor aberrations
- [metastatic dz, monotherapy]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo; Info: for pts w/ PD-L1-expressing tumor w/ dz progression on or after platinum-containing chemo
- [resectable dz, neoadjuvant tx, combo tx]
- Dose: 200 mg IV q3wk x12wk; Alt: 400 mg IV q6wk x12wk; Info: for pts w/ tumor >4cm or node-positive dz
- [resectable dz, adjuvant tx following neoadjuvant tx, monotherapy]
- Dose: 200 mg IV q3wk x39wk; Alt: 400 mg IV q6wk x39wk; Info: for pts w/ tumor >4cm or node-positive dz
- [stage IB, II, or IIIA dz, adjuvant tx, monotherapy]
- Dose: 200 mg IV q3wk for up to 12mo; Alt: 400 mg IV q6wk for up to 12mo; Info: following resection and platinum-based chemo
malignant pleural mesothelioma, unresectable advanced or metastatic
- [200 mg IV q3wk for up to 24mo]
- Alt: 400 mg IV q6wk for up to 24mo; Info: first-line tx; part of multi-drug chemo regimen
squamous cell head/neck CA
- [unresectable recurrent dz or metastatic dz, first-line tx, combo tx]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo
- [unresectable recurrent dz or metastatic dz, first-line tx, monotherapy]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo; Info: for pts w/ PD-L1-expressing tumor
- [recurrent or metastatic dz, monotherapy]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo; Info: for pts w/ dz progression on or after platinum-containing chemo
Hodgkin lymphoma, classical
- [200 mg IV q3wk for up to 24mo]
- Alt: 400 mg IV q6wk for up to 24mo; Info: for pts w/ relapsed or refractory dz
primary mediastinal large B-cell lymphoma, relapsed or refractory
- [200 mg IV q3wk for up to 24mo]
- Alt: 400 mg IV q6wk for up to 24mo; Info: for pts not requiring urgent cytoreductive tx
urothelial carcinoma
- [locally advanced or metastatic dz, combo tx]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo; Info: use w/ enfortumab vedotin
- [locally advanced or metastatic dz, monotherapy]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo; Info: for pts ineligible for cisplatin-containing chemo or pts w/ dz progression on or after platinum-containing chemo
- [non-muscle invasive bladder CA in situ, BCG-unresponsive, monotherapy]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo; Info: for pts w/ high-risk dz not undergoing cystectomy w/ or w/o papillary tumors
microsatellite instability-high or mismatch repair deficient solid tumors, unresectable or metastatic
- [200 mg IV q3wk for up to 24mo]
- Alt: 400 mg IV q6wk for up to 24mo; Info: for pts w/ progressive dz
microsatellite instability-high or mismatch repair deficient colorectal CA, unresectable or metastatic
- [200 mg IV q3wk for up to 24mo]
- Alt: 400 mg IV q6wk for up to 24mo
gastric CA, locally advanced unresectable or metastatic
- [HER2-positive PD-L1-expressing dz]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo; Info: for pts w/ gastric or gastroesophageal junction adenocarcinoma; first-line tx; part of multi-drug chemo regimen
- [HER2-negative dz]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo; Info: for pts w/ gastric or gastroesophageal junction adenocarcinoma; first-line tx; part of multi-drug chemo regimen
esophageal CA, locally advanced or metastatic
- [combo tx]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo; Info: for pts w/ esophageal or gastroesophageal junction CA not eligible for surgical resection or definitive chemoradiation
- [squamous cell recurrent dz, monotherapy]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo; Info: for pts w/ PD-L1 Combined Positive Score 10 or greater w/ esophageal or gastroesophageal junction CA not eligible for surgical resection or definitive chemoradiation
cervical CA
- [FIGO 2014 stage III-IVA dz, combo tx]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo
- [persistent, recurrent, or metastatic dz, combo tx]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo; Info: for pts w/ PD-L1-expressing tumor
- [recurrent or metastatic dz, monotherapy]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo; Info: for pts w/ PD-L1-expressing tumor w/ dz progression on or after chemo
hepatocellular CA, hepatitis B-associated
- [200 mg IV q3wk for up to 24mo]
- Alt: 400 mg IV q6wk for up to 24mo; Info: for pts who have received prior tx other than PD-1/PD-L1 inhibitor
biliary tract CA, locally advanced unresectable or metastatic
- [200 mg IV q3wk for up to 24mo]
- Alt: 400 mg IV q6wk for up to 24mo; Info: part of multi-drug chemo regimen
Merkel cell carcinoma, recurrent locally advanced or metastatic
- [200 mg IV q3wk for up to 24mo]
- Alt: 400 mg IV q6wk for up to 24mo
renal cell CA
- [advanced dz, first-line tx]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo; Info: use w/ axitinib or lenvatinib
- [adjuvant tx]
- Dose: 200 mg IV q3wk for up to 12mo; Alt: 400 mg IV q6wk for up to 12mo; Info: for pts w/ intermediate-high or high recurrence risk post-nephrectomy or pts post-nephrectomy and resection of metastatic lesions
endometrial carcinoma
- [advanced or recurrent dz, combo tx]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo
- [mismatch repair proficient or non-microsatellite instability-high dz, combo tx]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo; Info: for pts w/ advanced dz who have progressed after prior tx and not eligible for curative surgery or XRT; use w/ lenvatinib
- [mismatch repair deficient or microsatellite instability-high dz, monotherapy]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo; Info: for pts w/ advanced dz who have progressed after prior tx and not eligible for curative surgery or XRT
tumor mutational burden-high solid tumors, unresectable or metastatic
- [200 mg IV q3wk for up to 24mo]
- Alt: 400 mg IV q6wk for up to 24mo; Info: for pts w/ progressive dz
cutaneous squamous cell carcinoma
- [200 mg IV q3wk for up to 24mo]
- Alt: 400 mg IV q6wk for up to 24mo; Info: for pts w/ recurrent or metastatic dz, or locally advanced dz not curable by surgery or XRT
ER/PR-negative HER2-negative breast CA
- [high-risk early-stage dz, neoadjuvant tx, combo tx]
- Dose: 200 mg IV q3wk x24wk; Alt: 400 mg IV q6wk x24wk
- [high-risk early-stage dz, adjuvant tx following neoadjuvant tx, monotherapy]
- Dose: 200 mg IV q3wk for up to 27wk; Alt: 400 mg IV q6wk for up to 27wk (5 doses)
- [locally recurrent unresectable or metastatic dz, combo tx]
- Dose: 200 mg IV q3wk for up to 24mo; Alt: 400 mg IV q6wk for up to 24mo; Info: for pts w/ PD-L1 Combined Positive Score 10 or greater
small cell lung CA, relapsed (off-label)
- [200 mg IV q3wk for up to 24mo]
- Info: for pts who have received prior tx other than immune checkpoint inhibitors w/ chemo-free interval <6mo
renal dosing
- [see below]
- eGFR >15: no adjustment; eGFR <15: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin 1-3x ULN: no adjustment; bilirubin >3x ULN: not defined
Peds Dosing .
- Dosage forms: INJ
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments
melanoma
- [12 yo and older]
- Dose: 2 mg/kg/dose IV q3wk for up to 12mo; Max: 200 mg/dose; Info: for pts w/ stage IIB, IIC, or III dz as adjuvant tx
Hodgkin lymphoma, classical
- [2 mg/kg/dose IV q3wk for up to 24mo]
- Max: 200 mg/dose; Info: for pts w/ refractory dz or relapsed dz after at least 2 lines of tx
primary mediastinal large B-cell lymphoma, relapsed or refractory
- [2 mg/kg/dose IV q3wk for up to 24mo]
- Max: 200 mg/dose; Info: for pts not requiring urgent cytoreductive tx
microsatellite instability-high or mismatch repair deficient solid tumors, unresectable or metastatic
- [2 mg/kg/dose IV q3wk for up to 24mo]
- Max: 200 mg/dose; Info: for pts w/ progressive dz
Merkel cell carcinoma, recurrent locally advanced or metastatic
- [2 mg/kg/dose IV q3wk for up to 24mo]
- Max: 200 mg/dose
tumor mutational burden-high solid tumors, unresectable or metastatic
- [2 mg/kg/dose IV q3wk for up to 24mo]
- Max: 200 mg/dose; Info: for pts w/ progressive dz; not for pts w/ CNS cancers
renal dosing
- [see below]
- eGFR >15: no adjustment; eGFR <15: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin 1-3x ULN: no adjustment; bilirubin >3x ULN: not defined